Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07324850

A Study of SGB-7342 in Subjects With Obesity or Overweight

The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obesity & Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
  • Have a stable body weight within 3 months
  • Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
  • Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.

Exclusion criteria

  • A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
  • Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
  • Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
  • Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators

Treatment and study plan

SGB-7342

Drug

SC injection, single dose

SGB-7342-Matching placebo

Drug

Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: up to approximately 6 months

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: up to approximately 3 days

  2. Area Under the Concentration-time Curve (AUC)

    Time frame: up to 3 days

  3. Weight change from baseline

    Time frame: up to approximately 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

SGB.clinical

CONTACT

[email protected]

+086 021-60209828

Sponsors and collaborators

Lead sponsor

Suzhou Sanegene Bio Inc.

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 8, 2026
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.